mRNA– tag –
-
Nanoparticles Show Promise for Targeted Drug Delivery in Heart Failure: Applications for Fibrosis, Inflammation, and Gene Therapies
Circulation (AHA Journals) USA Overview Nanoparticle-based approaches are emerging as promising strategies to enhance targeted drug delivery for heart failure, addressing key pathophysiological areas such as TGF-β-mediated fibrosis, IL-1... -
2026 ‘In Vivo CRISPR Medicine’ Symposium to Focus on Commercialization and Scalable Deployment of In Vivo Genome Editing
CRISPR Medicine News (CMN x CSGCT Virtual Symposium) USA Overview The upcoming 'In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale' virtual symposium on September 3, 2026, will highlight the transition of in vivo genom... -
Extracellular Vesicles Emerge as Promising Biomarkers and Therapeutics for Cardiovascular Disease
Exosome-RNA.com USA Overview Researchers at Massachusetts General Hospital have highlighted the significant potential of extracellular vesicles (EVs) as both diagnostic biomarkers and therapeutic agents for cardiovascular diseases (CVD).... -
PackGene Biotech’s π-alpha 293 Platform Achieves 10x AAV Production Amplification, Up to 1e+17vg/Batch, Supporting Remedium Bio’s Gene Therapy Advancement
PackGene Biotech China Overview PackGene Biotech announced its innovative π-alpha 293 AAV high-yield platform, capable of amplifying adeno-associated virus (AAV) production up to 10-fold and achieving an impressive yield of up to 1e+17vg... -
Biologics and GLP-1 Agonists Drive Acceleration of Automation and Digitization in Fill-Finish Manufacturing
BioProcess Online USA Overview The rapid rise of biologics—including antibody-drug conjugates (ADCs), cell & gene therapies, and mRNA products—and GLP-1 receptor agonists is accelerating the evolution of fill-finish manufacturing pro... -
Maravai LifeSciences Sustains Revenue Outlook in Q2, Strategically Reinforces TriLink’s mRNA, CDMO, and Specialty Chemistry Focus
TradingView USA Overview Maravai LifeSciences confirmed its Q2 revenue guidance, demonstrating resilience amidst fluctuations in large-scale CDMO projects and GMP consumables. The company reported consistent growth in smaller and mid-siz... -
AI and CDMO Synergy Accelerates End-to-End mRNA Therapeutic Development
SyVento BioTech Poland Overview SyVento BioTech and nCode have forged a strategic partnership to revolutionize mRNA therapeutic development. This collaboration seamlessly integrates nCode's AI-powered mRNA sequence optimization with SyVe... -
AGC Biologics Secures Multi-Million Dollar Manufacturing Deal for Yokohama Facility, Boosting LNP Production Capacity
히트뉴스 Japan Overview AGC Biologics, a global CDMO, has secured a multi-year commercial manufacturing contract, valued at hundreds of millions of dollars, for its new Yokohama facility in Japan, slated to open in 2027. An undisclosed b... -
Pharmaceutical Formulation Development Soars with LNP-Delivered mRNA Vaccines, Yet Poor Drug-Like Properties (Solubility, Permeability, PK) Account for 10-15% of Development Failures
IntuitionLabs.ai Singapore Overview Pharmaceutical formulation development has increased in complexity and importance with the advent of lipid nanoparticle (LNP)-delivered messenger RNA (mRNA) vaccines. A 2010-2017 clinical trial data re... -
Roivant Sciences Receives $771.6 Million Settlement from Moderna Lawsuit, Enters Cross-Licensing Agreement for LNP and GalNAc Technologies
Stock Titan USA Overview Roivant Sciences announced it received a $771.6 million settlement from a lawsuit with Moderna. The settlement includes a comprehensive cross-licensing agreement where Moderna grants Genevant/Arbutus non-exclusiv...
